The SUMO Pathway in Hematomalignancies and Their Response to Therapies
Equipe Labellisée Ligue Contre le Cancer, Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, 34000 Montpellier, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(16), 3895; https://doi.org/10.3390/ijms20163895
Received: 9 July 2019
/
Revised: 31 July 2019
/
Accepted: 6 August 2019
/
Published: 9 August 2019
(This article belongs to the Special Issue Drug Resistance in Hematologic Malignancies)
SUMO (Small Ubiquitin-related MOdifier) is a post-translational modifier of the ubiquitin family controlling the function and fate of thousands of proteins. SUMOylation is deregulated in various hematological malignancies, where it participates in both tumorigenesis and cancer cell response to therapies. This is the case for Acute Promyelocytic Leukemias (APL) where SUMOylation, and subsequent destruction, of the PML-RARα fusion oncoprotein are triggered by arsenic trioxide, which is used as front-line therapy in combination with retinoic acid to cure APL patients. A similar arsenic-induced SUMO-dependent degradation was also documented for Tax, a human T-cell lymphotropic virus type I (HTLV1) viral protein implicated in Adult T-cell Leukemogenesis. SUMOylation also participates in Acute Myeloid Leukemia (AML) response to both chemo- and differentiation therapies, in particular through its ability to regulate gene expression. In Multiple Myeloma, many enzymes of the SUMO pathway are overexpressed and their high expression correlates with lower response to melphalan-based chemotherapies. B-cell lymphomas overexpressing the c-Myc oncogene also overexpress most components of the SUMO pathway and are highly sensitive to SUMOylation inhibition. Targeting the SUMO pathway with recently discovered pharmacological inhibitors, alone or in combination with current therapies, might therefore constitute a powerful strategy to improve the treatment of these cancers.
View Full-Text
Keywords:
SUMOylation; leukemia; hematomalignancies; resistance
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Boulanger, M.; Paolillo, R.; Piechaczyk, M.; Bossis, G. The SUMO Pathway in Hematomalignancies and Their Response to Therapies. Int. J. Mol. Sci. 2019, 20, 3895. https://doi.org/10.3390/ijms20163895
AMA Style
Boulanger M, Paolillo R, Piechaczyk M, Bossis G. The SUMO Pathway in Hematomalignancies and Their Response to Therapies. International Journal of Molecular Sciences. 2019; 20(16):3895. https://doi.org/10.3390/ijms20163895
Chicago/Turabian StyleBoulanger, Mathias, Rosa Paolillo, Marc Piechaczyk, and Guillaume Bossis. 2019. "The SUMO Pathway in Hematomalignancies and Their Response to Therapies" International Journal of Molecular Sciences 20, no. 16: 3895. https://doi.org/10.3390/ijms20163895
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
